The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

While first-generation glucagon-like peptide-1 receptor agonists have clearly taken the obesity market by storm, generating billions of dollars for Novo Nordisk A/S and Eli Lilly and Co., several ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Novo Nordisk's semaglutide sales are enormous, but it's losing ground to tirzepatide, a more recently launched drug from Eli Lilly(NYSE: LLY) that acts on GLP-1 and GIP receptors. The dual agonist ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...